Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...
News Medical on MSN11h
Researchers develop new tool to assess psychological impact of esophageal diseases
Psychological factors have a greater impact on the severity of symptoms in esophageal diseases than objective evaluations, ...
Photodynamic Therapies In Oncology Market Is Predicted To Exhibit Remarkable Growth During The Study Period (2020–2034) | Delveinsight
The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patien ...